Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Change in Accured Expenses readings, the most recent being -$5.0 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 40.35% to -$5.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $36.0 million, a 2.18% decrease, with the full-year FY2025 number at $37.5 million, down 14.25% from a year prior.
  • Change in Accured Expenses hit -$5.0 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $19.6 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $19.6 million in Q4 2025 to a low of -$10.6 million in Q1 2023.
  • Median Change in Accured Expenses over the past 5 years was $5.3 million (2023), compared with a mean of $5.3 million.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 456.87% in 2022 and later soared 345.95% in 2023.
  • Kiniksa Pharmaceuticals International's Change in Accured Expenses stood at -$3.8 million in 2022, then soared by 239.44% to $5.3 million in 2023, then soared by 107.96% to $11.0 million in 2024, then soared by 78.54% to $19.6 million in 2025, then crashed by 125.71% to -$5.0 million in 2026.
  • The last three reported values for Change in Accured Expenses were -$5.0 million (Q1 2026), $19.6 million (Q4 2025), and $8.4 million (Q3 2025) per Business Quant data.